55.09
price down icon0.09%   -0.05
after-market After Hours: 56.46 1.37 +2.49%
loading
Crispr Therapeutics Ag stock is traded at $55.09, with a volume of 2.14M. It is down -0.09% in the last 24 hours and up +27.55% over the past month. Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
See More
Previous Close:
$55.14
Open:
$55.85
24h Volume:
2.14M
Relative Volume:
0.81
Market Cap:
$4.76B
Revenue:
$170.10M
Net Income/Loss:
$-239.59M
P/E Ratio:
-19.68
EPS:
-2.8
Net Cash Flow:
$-191.20M
1W Performance:
-6.63%
1M Performance:
+27.55%
6M Performance:
+35.92%
1Y Performance:
-8.91%
1-Day Range:
Value
$54.80
$56.20
1-Week Range:
Value
$52.33
$59.48
52-Week Range:
Value
$30.04
$62.00

Crispr Therapeutics Ag Stock (CRSP) Company Profile

Name
Name
Crispr Therapeutics Ag
Name
Phone
(617) 315-4600
Name
Address
BAARERSTRASSE 14, ZUG
Name
Employee
393
Name
Twitter
@crisprtx
Name
Next Earnings Date
2024-12-05
Name
Latest SEC Filings
Name
CRSP's Discussions on Twitter

Compare CRSP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CRSP
Crispr Therapeutics Ag
55.09 5.10B 170.10M -239.59M -191.20M -2.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
463.27 123.14B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
550.00 60.43B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.69 42.07B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
572.71 34.47B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
290.35 27.42B 3.81B -644.79M -669.77M -6.24

Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-14-25 Upgrade Evercore ISI In-line → Outperform
Feb-12-25 Upgrade TD Cowen Sell → Hold
Feb-03-25 Initiated H.C. Wainwright Buy
Aug-06-24 Reiterated Needham Buy
Aug-02-24 Initiated Rodman & Renshaw Buy
Jun-28-24 Resumed Guggenheim Neutral
Feb-15-24 Initiated Wolfe Research Peer Perform
Dec-11-23 Downgrade TD Cowen Market Perform → Underperform
Oct-17-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Sep-27-23 Initiated Mizuho Buy
Aug-17-23 Upgrade Citigroup Neutral → Buy
May-30-23 Initiated William Blair Outperform
Apr-13-23 Initiated Cantor Fitzgerald Overweight
Mar-21-23 Initiated Bernstein Mkt Perform
Mar-17-23 Initiated Bryan Garnier Buy
Mar-07-23 Initiated Robert W. Baird Neutral
Oct-11-22 Initiated Morgan Stanley Underweight
Aug-09-22 Downgrade Barclays Overweight → Equal Weight
Jun-23-22 Downgrade Evercore ISI Outperform → In-line
Jun-17-22 Initiated BMO Capital Markets Outperform
Apr-28-22 Initiated Credit Suisse Neutral
Dec-07-21 Initiated Cowen Market Perform
Oct-19-21 Initiated SVB Leerink Outperform
Jun-14-21 Upgrade Citigroup Sell → Neutral
Apr-21-21 Upgrade Jefferies Hold → Buy
Mar-04-21 Initiated JMP Securities Mkt Outperform
Dec-10-20 Reiterated Chardan Capital Markets Buy
Dec-10-20 Downgrade Jefferies Buy → Hold
Dec-10-20 Reiterated Needham Buy
Dec-07-20 Downgrade Wells Fargo Overweight → Equal Weight
Oct-23-20 Initiated RBC Capital Mkts Sector Perform
Oct-05-20 Initiated BofA Securities Buy
Jul-28-20 Reiterated Needham Buy
Jul-14-20 Initiated SunTrust Buy
Jun-15-20 Reiterated Canaccord Genuity Buy
Mar-05-20 Initiated Stifel Hold
Feb-03-20 Downgrade Evercore ISI Outperform → In-line
Nov-19-19 Upgrade William Blair Mkt Perform → Outperform
Nov-12-19 Upgrade Oppenheimer Perform → Outperform
Aug-01-19 Initiated Jefferies Buy
Jul-26-19 Initiated Canaccord Genuity Buy
Jun-10-19 Initiated ROTH Capital Buy
Apr-12-19 Initiated Evercore ISI Outperform
Mar-14-19 Initiated William Blair Mkt Perform
Jan-28-19 Downgrade Goldman Buy → Neutral
Jan-22-19 Downgrade Citigroup Neutral → Sell
View All

Crispr Therapeutics Ag Stock (CRSP) Latest News

pulisher
Jul 17, 2025

Director Makes Multi-Million Dollar Investment in Crispr Therapeutics AG! - TipRanks

Jul 17, 2025
pulisher
Jul 16, 2025

CRISPR Therapeutics (CRSP) Moves 9.6% Higher: Will This Strength Last? - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

Leavell Investment Management Inc. Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Jul 16, 2025
pulisher
Jul 16, 2025

William Blair Issues Positive Outlook for CRSP Earnings - MarketBeat

Jul 16, 2025
pulisher
Jul 16, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Jul 16, 2025
pulisher
Jul 16, 2025

Is It Worth Investing in CRISPR Therapeutics (CRSP) Based on Wall Street's Bullish Views? - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 5.7%Here's What Happened - MarketBeat

Jul 15, 2025
pulisher
Jul 15, 2025

B & T Capital Management DBA Alpha Capital Management Buys New Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Jul 15, 2025
pulisher
Jul 14, 2025

(CRSP) Trading Report - news.stocktradersdaily.com

Jul 14, 2025
pulisher
Jul 14, 2025

Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade) - Seeking Alpha

Jul 14, 2025
pulisher
Jul 12, 2025

Crispr Therapeutics AG Stock Soars Amid Strategic Moves - TipRanks

Jul 12, 2025
pulisher
Jul 12, 2025

CRISPR Therapeutics (CRSP) Jumps 9.6% on Biotech Rally - MSN

Jul 12, 2025
pulisher
Jul 12, 2025

CRISPR Therapeutics Target of Unusually Large Options Trading (NASDAQ:CRSP) - MarketBeat

Jul 12, 2025
pulisher
Jul 11, 2025

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com

Jul 11, 2025
pulisher
Jul 11, 2025

Genome Engineering Market Booming as CRISPR and Gene Editing - openPR.com

Jul 11, 2025
pulisher
Jul 11, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 7%Should You Buy? - MarketBeat

Jul 11, 2025
pulisher
Jul 10, 2025

CRISPR Stock Surges in Recent Weeks: What's Going On?CRISPR Therapeutics (NASDAQ:CRSP) - Benzinga

Jul 10, 2025
pulisher
Jul 09, 2025

10 Stocks Going Wild - Insider Monkey

Jul 09, 2025
pulisher
Jul 09, 2025

CRISPR’s Medical Breakthrough: Stock Surge or Mirage? - StocksToTrade

Jul 09, 2025
pulisher
Jul 09, 2025

CRISPR Therapeutics (NasdaqGM:CRSP) Advances Cardiovascular Programs With Promising Trial Results - Yahoo Finance

Jul 09, 2025
pulisher
Jul 09, 2025

CRISPR Therapeutics Rises Amid Positive Cardiovascular Trials - timothysykes.com

Jul 09, 2025
pulisher
Jul 09, 2025

CRISPR Therapeutics’ Bold Leap: A Revolution in Cardiovascular Treatment? - StocksToTrade

Jul 09, 2025
pulisher
Jul 08, 2025

CRISPR Therapeutics Reports Landmark Advances in Cardiovascular Trials - timothysykes.com

Jul 08, 2025
pulisher
Jul 08, 2025

Crispr Therapeutics AG: Strategic Positioning and Growth Potential in Gene Editing - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market - MSN

Jul 08, 2025
pulisher
Jul 07, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Boosted by Cambridge Investment Research Advisors Inc. - MarketBeat

Jul 07, 2025
pulisher
Jul 07, 2025

CRISPR Therapeutics’ SWOT analysis: gene-editing pioneer’s stock faces pivotal year - Investing.com

Jul 07, 2025
pulisher
Jul 05, 2025

Crispr Therapeutics AG Stock Soars Amid Clinical Advances - TipRanks

Jul 05, 2025
pulisher
Jul 03, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 7.1%Here's Why - MarketBeat

Jul 03, 2025
pulisher
Jul 01, 2025

Wealth Enhancement Advisory Services LLC Boosts Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Jul 01, 2025
pulisher
Jun 30, 2025

CRISPR Therapeutics AG(NasdaqGM: CRSP) added to Russell 2000 Dynamic Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Crispr Therapeutics’ Stock Surges on Promising Study Update - TipRanks

Jun 30, 2025
pulisher
Jun 30, 2025

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - MSN

Jun 30, 2025
pulisher
Jun 28, 2025

Brookline Capital Markets Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail

Jun 28, 2025
pulisher
Jun 27, 2025

Goldman Sachs Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail

Jun 27, 2025
pulisher
Jun 27, 2025

Crispr Therapeutics downgraded to Hold from Buy at Clear Street - TipRanks

Jun 27, 2025
pulisher
Jun 26, 2025

CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing - MSN

Jun 26, 2025
pulisher
Jun 26, 2025

CRISPR Therapeutics Reports Positive Additional Phase 1 - GlobeNewswire

Jun 26, 2025
pulisher
Jun 26, 2025

CRISPR Therapeutics (CRSP) Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 - StreetInsider

Jun 26, 2025
pulisher
Jun 26, 2025

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline - GlobeNewswire

Jun 26, 2025
pulisher
Jun 26, 2025

CRISPR Breakthrough: New Drug Slashes Heart Disease Risk with 86% Cholesterol Reduction in Clinical Trial - Stock Titan

Jun 26, 2025
pulisher
Jun 25, 2025

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - Yahoo Finance

Jun 25, 2025
pulisher
Jun 24, 2025

CRISPR Therapeutics AG (CRSP): A Bull Case Theory - Yahoo Finance

Jun 24, 2025
pulisher
Jun 21, 2025

Crispr Therapeutics: Face The Harsh Reality Instead Of Waiting (Rating Downgrade) - Seeking Alpha

Jun 21, 2025
pulisher
Jun 20, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap UpWhat's Next? - MarketBeat

Jun 20, 2025
pulisher
Jun 19, 2025

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? - Yahoo Finance

Jun 19, 2025
pulisher
Jun 18, 2025

CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Traders Buy High Volume of Call Options on CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

From Now to 2032: Unpacking the Genome Editing Market's - openPR.com

Jun 18, 2025
pulisher
Jun 18, 2025

CRISPR Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com

Jun 18, 2025

Crispr Therapeutics Ag Stock (CRSP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$22.01
price up icon 0.64%
$35.47
price down icon 0.37%
$104.17
price down icon 0.40%
$27.63
price down icon 2.26%
$111.04
price down icon 1.29%
biotechnology ONC
$290.35
price up icon 4.01%
Cap:     |  Volume (24h):